Suppr超能文献

基于断层放射治疗的全骨髓联合全淋巴照射预处理在急性白血病造血干细胞移植中的临床研究

Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia.

作者信息

Kong Fanyang, Liu Shuaipeng, Liu Lele, Pi Yifei, Pei Yuntong, Xu Dandan, Jia Fei, Han Bin, Guo Yuexin

机构信息

Department of Radiation Therapy, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

出版信息

Front Oncol. 2022 Aug 11;12:936985. doi: 10.3389/fonc.2022.936985. eCollection 2022.

Abstract

OBJECTIVE

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method for the treatment of refractory and relapsed acute leukemia, and the preconditioning methods before transplantationis one of the important factors affecting the survival of patients. Radiotherapy combined with chemotherapy is the most commonly used preconditioning method before transplantation. This study evaluated the safety and efficacy of total bone marrow combined with total lymphatic irradiation as a preconditioning method before hematopoietic stem cell transplantation.

METHODS

Seventeen patients with acute leukemia who were admitted to our center from 2016 to 2020 were selected. The median age was 17 years (8-35). The target area for TMLI includes the total bone marrow and total lymphatic space, and the organs at risk include the lens, lungs, kidneys, intestine, heart, and liver. The patients received a total bone marrow and lymphatic irradiation preconditioning regimen, the related acute adverse reactions were graded, and the prognosis of the patients after transplantation was observed.

RESULTS

During patient preconditioning, only grade 1-2 toxicity was observed, and grade 3-4 toxicity did not occur. Except for one patient whose platelets were not engrafted, all the other patients were successfully transplanted. The median time of neutrophil implantation was 14 d (9-15 d), and the median time of platelet implantation was 14 d (13-21 d). With a median follow-up of 9 months (2-48), 4 relapses occurred, 3 died, and 10 leukemia patients survived and were disease-free. One-year overall survival was 69.8%, cumulative recurrence was 19.5%, disease-free-survival was 54.2%.

CONCLUSION

The Allo-HSCT pretreatment regimen of total bone marrow combined with total lymphatic irradiation is safe and effective in the treatment of malignant hematological diseases. Total bone marrow combined with total lymphatic irradiation may completely replace total body irradiation, and the clinically observed incidence of acute toxicity is not high.

摘要

目的

异基因造血干细胞移植(allo-HSCT)是治疗难治性和复发性急性白血病的有效方法,移植前的预处理方法是影响患者生存的重要因素之一。放疗联合化疗是移植前最常用的预处理方法。本研究评估了全骨髓联合全淋巴照射作为造血干细胞移植前预处理方法的安全性和有效性。

方法

选取2016年至2020年入住本中心的17例急性白血病患者。中位年龄为17岁(8 - 35岁)。全淋巴照射的靶区包括全骨髓和全淋巴间隙,危及器官包括晶状体、肺、肾、肠、心脏和肝脏。患者接受全骨髓和淋巴照射预处理方案,对相关急性不良反应进行分级,并观察患者移植后的预后情况。

结果

在患者预处理期间,仅观察到1 - 2级毒性反应,未发生3 - 4级毒性反应。除1例患者血小板未植入外,其他患者均成功移植。中性粒细胞植入的中位时间为14天(9 - 15天),血小板植入的中位时间为14天(13 - 21天)。中位随访9个月(2 - 48个月),发生4例复发,3例死亡,10例白血病患者存活且无病。1年总生存率为69.8%,累积复发率为19.5%,无病生存率为54.2%。

结论

全骨髓联合全淋巴照射的异基因造血干细胞移植预处理方案治疗恶性血液病安全有效。全骨髓联合全淋巴照射可能完全替代全身照射,临床观察到的急性毒性发生率不高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab25/9425557/35029fc03ac9/fonc-12-936985-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验